First Aid Antibiotic Antibiotics

A Measure of the Efficacy of Bwell First Aid Antibiotic Against Six Common Bacteria

Abstract

This study is an efficacy study of Bwell First Aid Antibiotic against six common bacteria. The six bacteria used in this study were E.coli, Pseudomonas aeruginosa, Coagulase negative Staphylococcus aureus (CNSA), Methacillin resistant Staphylococcus aureus (MRSA), Methacillin Susceptible Staphylococcus aureus (MSSA), and Mupirocin resistant Staphylococcus aureus (MuRSA). Report results are the combined average of three trials: two independent and one blind. Each followed the same protocol and used the same product.

The bacteria were grown in pure culture and each was suspended in phosphate buffered saline (PBS). It was found that the preparation of Bwell First Aid Antibiotic formulation killed more than 99.0% of E.coli, P. aeruginosa, CNSA, MRSA, MSSA, and MuRSA. Bwell First Aid Antibiotic killed greater than 99% of common resistant bacteria.

Introduction

The purpose of this study was to compare the efficacy of Bwell First Aid Antibiotic. Bwell First Aid Antibiotic is a First Aid antibiotic ointment with 3% Tetracycline Hydrochloride delivered by Dual Carrier Technology (DCT). The DCT is a tissue penetration technology that creates releasable binds to the active pharmaceutical ingredient, as the carrier transports the drug in a high penetration format through the pathogen cell wall to effectively kill the bacteria and reduce the water activity level (e.g. dehydrate) in the bacteria, for both a pharmaceutical and mechanical kill.

Method

Bwell was provided by Inventus, LLC. Six bacteria were grown in pure culture and each was suspended in phosphate buffered saline (PBS). The bacterial suspension was mixed with 30ul or 30ug of each of the antimicrobial products. 30ul was used for the Bwell First Aid Antibiotic Ointment. Three replicates were completed for each bacteria/antimicrobial product combination at separate time points. A control containing each bacterium without an antimicrobial product was completed per bacterium per replication. The mixtures were incubated for 4 hours at 37°C and plated onto blood agar plates. The plates were incubated for 24 hours at 37°C. The colony forming units per milliliter (CFUs/ml) were counted and compared to the control.

Materials

Antimicrobial Product

  1. Bwell First Aid Antibiotic

Bacteria

  1. E. coli
  2. Pseudomonas aeruginosa ATCC # 27853
  3. LAC USA 300 MRSA
  4. Coagulase negative Staph. aureus
  5. MN8 USA 200 MSSA
  6. 1179 Mupirocin resistant Staph. Aureus

Results

The following table and data were collected by RTI, Inc. of Brookings, SD

 

Summary of results from Efficacy Evaluation

E. coli: Bwell First Aid Antibiotic preparation killed on an average 99.18% of

E.coli.

Pseudomonas aeruginosa: Bwell First Aid Antibiotic preparation killed on an average 99.61%

P. Aeruginosa.

Methicillin resistant staphylococcus aureus (MRSA): Bwell First Aid Antibiotic preparation killed on an average 99.65%

MRSA. Coagulase negative staph aureus (CNSA): Bwell First Aid Antibiotic preparation killed on average 98.15% CNSA.

Methicillin susceptible staphylococcus aureus (MSSA): The Bwell First Aid Antibiotic preparation killed on average 99.55% MSSA.

Mupirocin resistant staphylococcus aureus (MuRSA): Bwell First Aid Antibiotic preparation killed on average 99.57% MuRSA.

 

Overall Conclusion of Comparative Efficacy Study

In this study the effects of Bwell First Aid Antibiotic preparations on the growth of E.coli, Pseudomonas aeruginosa, Coagulase negative Staphylococcus aureus (CNSA), Methacillin resistant staphylococcus aureus (MRSA), Methacillin susceptible staphylococcus aureus (MSSA), and Mupirocin resistant staphylococcus aureus (MuRSA) was studied. It was found that the Bwell First Aid Antibiotic preparation killed more than 99.0% of E.coli, P. aeruginosa, MRSA, MSSA, and MuRSA and greater than 98.0% of CNSA. Bwell First Aid Antibiotic effectively kills six common bacteria.


This project was overseen by South Dakota State University School of Pharmacy in collaboration with Rural Technology Incorporated and a blind third party laboratory. This study was and funded by Inventus, LLC.

Read More